Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21189802 | 0.86 | USP2 (0.33) | USP2 | |
| SCHEMBL21861807 | 0.85 | PAOX (0.36) | KDM4EALDH1A1PKMDNM1CA1 | |
| SCHEMBL23964448 | 0.83 | KISS1R (0.31) | — | |
| SCHEMBL20644790 | 0.81 | KDM4E (0.33) | KDM4EALDH1A1PKMDNM1CA1 | |
| SCHEMBL19756275 | 0.81 | KDM4E (0.33) | KDM4EALDH1A1PKMDNM1CA1 | |
| SCHEMBL19756280 | 0.81 | KDM4E (0.33) | KDM4EALDH1A1PKMDNM1CA1 | |
| SCHEMBL20670283 | 0.81 | KDM4E (0.33) | KDM4EALDH1A1PKMDNM1CA1 | |
| SCHEMBL21536841 | 0.80 | KDM4E (0.33) | KDM4EALDH1A1PKMDNM1CA1 | |
| SCHEMBL21540214 | 0.79 | KDM4E (0.34) | KDM4EALDH1A1PKMDNM1 | |
| SCHEMBL21540324 | 0.79 | KDM4E (0.34) | KDM4EALDH1A1PKMDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | ASCENDIS PHARMA A/S (DK) | 2021-11-04 | — | — | US | disclosed |
| US-20210330807-A1 | NOVEL HYDROGEL CONJUGATES | ASCENDIS PHARMA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | CD44, HPSE, MMP13 | KDM4E 2703/4885ALDH1A1 101/4885PKM 1859/4885 |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | H1-10, PM20D2, ELANE | KDM4E 3614/4885ALDH1A1 1667/4885PKM 3529/4885 |
| US-20210330807-A1 | NOVEL HYDROGEL CONJUGATES | CD44, MSN, TBCA | KDM4E 3054/4885ALDH1A1 152/4885PKM 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.